NEUROPROTECTION IN BRAIN ISCHEMIA – DOUBTS AND HOPES;NEUROPROTEKCIÓ AGYI ISCHAEMIÁBAN – KÉTELYEK ÉS REMÉNYEK

Ideggyogyaszati Szemle

Volumn 57, Issue 3-4, 2004, Pages 81-93

  Zsolt, Zádor ^a   Zoltán, Benyó ^b   Zsombor, Lacza ^b   Tibor, Id Hortobágyi ^c   Tibor, Harkány ^a   Tibor, Hortobágyi ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Nagykanizsa Megyei Jogú Város Kórháza   (Hungary)

Author keywords

clinical trials; ischemia; neuroprotection; stroke

Indexed keywords

4 AMINOBUTYRIC ACID; CALCIUM CHANNEL; EXCITATORY AMINO ACID; FREE RADICAL; GROWTH PROMOTOR; INTERCELLULAR ADHESION MOLECULE 1; NEUROPROTECTIVE AGENT;

ANIMAL; APOPTOSIS; BRAIN CIRCULATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; REVIEW;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; CALCIUM CHANNELS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACIDS; FREE RADICALS; GAMMA-AMINOBUTYRIC ACID; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; NEUROPROTECTIVE AGENTS;

EID: 3042576470     PISSN: 00191442     EISSN: 24986208     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994;25:1901-14.
2. Nagy Z. Az agyérbetegségek epidemiológiája. In: Nagy Z (ed). Stroke-ellátás. Budapest: Springer-Verlag; 1994. p. 19-28.
3. Hass WK. The cerebral ischemic cascade. Neurol Clin 1983;1:345-53.
4. NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-25.
5. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
6. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
7. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-26.
8. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-8.
9. Donnan G. Streptokinase for acute ischemic stroke with relationship to time administration. JAMA 1996;276:961-6.
10. Multicenter Acute Stroke Trial-European Study Group. Thrombolitic therapy with streptokinase in acute ischemic stroke. N Eng J Med 1996;335:145-50.
11. Multicenter Acute Stroke Trial-Italy (MAST-1) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 1995;346:1509-14.
12. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-605.
13. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. The American Nimodipine Study Group. Stroke 1992;23:3-8.
14. Hennerici M, Kramer G, North PM, et al. Nimodipine in the treatment of acute MCA ischemic stroke. Cerebrovasc Dis 1994;4:189-93.
15. Mohr JP, Orgogozo JM, Harrison MJG, et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994;4:197-203.
16. Horn J, Limburg M, Vermeulen M. VENUS very early nimodipine use in stroke: Final results from a randomised, placebo-controlled trial. Cerebrovasc Dis 1999;9 (Suppl1):127.
17. Wahlgren NG, MacMahon DG, De Keyser J, et al. Intravenous nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4: 204-10.
18. Brigers S, Koch G, Munera C, et al. Intravenous nimodipine in acute stroke: Interim analysis of randomized trial. Stroke 1991;22:29.
19. Oczkowski WJ, Hachinski VC, Bogousslavsky J, et al. A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke 1989;20:604-8.
20. Franke CL, Palm R, Dalby M, et al. Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 1996;93:56-60.
21. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Database Syst Rev 2000;2:CD001928.
22. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-7.
23. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
24. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 1997;28:2338-46.
25. Lees KR. Does neuroprotection improve stroke outcome? Lancet 1998;35:1447-8.
26. Pulsinelli WA, Mann ME, Welch KMA, et al. Fosphenytoin in acute ischemic stroke: Efficacy result. Neurology 1999;52(suppl2):A384.
27. Huber M, Kittner B, Hojer C, et al. Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993;13:526-30.
28. Squire IB, Lees KR, Pryse-Phillips W, et al for the Lifarizine Study Group. Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Ann NY Acad Sci 1995;765:317-8.
29. Albers GW, Atkinson RP, Kelley RE, et al. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 1995;26:254-8.
30. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Ann NY Acad Sci 1995;765:315-6.
31. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(Suppl4):S66-9.
32. Gorgulu A, Kins T, Cobanoglu S, et al. Reduction of edema by Memantine and MK-801 after focal cerebral ischemia and reperfusion in rat. Acta Neurochir (Wien) 2000; 142:1287-92.
33. Stieg PE, Sathi S, Warach S, et al. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol 1999;375:115-20.
34. Davis SM, Albers GW, Diener HC, et al. Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Committed. Lancet 1997;349:32.
35. Giroux C, Rosen P, Scatton B. Preclinical pharmacology and clinical safety profile of eliprodil, an atypical NMDA receptor antagonist. In: Krieglstein J, Oberpichler-Schwenk H (eds.). Pharmacology of Cerebral Ischemia. Stuttgart: Medpharm Scientific; 1994. p. 643-8.
36. Warach S, Kaste M, Fisher M, on behalf of the GAIN Americas and GAIN Internatinal MRI substudy investigators and Galaxo Wellcome Collaborative Group. The effect of GV 150526 on ischemic lesion volume: The GAIN Americas and GAIN International MRI substudy. Neurology 2000;54(suppl3):A87-A88.
37. Haley EC Jr. On behalf of the RANTTAS II Investigators. High-dose tirilazad for acute stroke (RANTTAS II). Stroke 1998;29:1256-7.
38. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-7.
39. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al for the Ebselen Study Group. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke 1998;29:12-7.
40. Dawson DA. Nitric oxide and focal cerebral ischemia: multiplicity of actions and diverse outcome. Cerebrovasc Brain Metab Rev 1994;6:299-324.
41. Nishikawa T, Kirsch JR, Koehler RC, et al. Nitric oxide synthase inhibition reduces caudate injury following transient focal ischemia in cats. Stroke 1994;25:877-85.
42. O’Mahony D, Kendall MJ. Nitric oxide in acute ischaemic stroke: a target for neuroprotection. J Neurol Neurosurg Psychiatry 1999;67:1-3.
43. Koketsu N, Berlove DJ, Moskowitz MA, et al. Pretreatment with intraventricular basic fibroblast growth factor decreases infarct size following focal cerebral ischemia in rats. Ann Neurol 1994;35:451-7.
44. Clark WM, Schim JD, Kasner SE, et al, the Fiblast Stroke Study Investigators. Trafermin in acute ischemic stroke: Results of a phase I/II randomized efficacy study. Neurology 2000;54(suppl3):A88.
45. Bogousslavsky J, Victor SJ, Salinas EO, et al. European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 2002;14:239-51.
46. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399 (Suppl):A7-14.
47. Hortobágyi T, Nagy Z. Az apoptózis jellemzõi és szerepe az ischaemiás agykárosodásban. Lege Artis Med 1997; 7:462-71.
48. Zádor Z, Lacza Z, Benyó Z, et al. Apoptózis fokális agyi ischaemiában. Ideggy Szemle 2003;56:(7-8):216-28.
49. Nyakas C, Oosterink BJ, Keijser J, et al. Selective decline of 5-HT1A receptor binding sites in rat cortex, hippocampus and cholinergic basal forebrain nuclei during aging. J Chem Neuroanat 1997;13:53-61.
50. Khateb A, Fort P, Alonso A, et al. Pharmacological and immunohistochemical evidence for serotonergic modulation of cholinergic nucleus basalis neurons. Eur J Neurosci 1993;5:541-7.
51. Ahlemeyer B, Beier H, Semkova I, et al. S-100beta protects cultured neurons against glutamate- and staurosporineinduced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay x 3702. Brain Res 2000;858:121-8.
52. Kukley M, Schaper C, Becker A, et al. Effect of 5-hydroxy-tryptamine 1A receptor agonist Bay x 3702 on BCL-2 and BAX proteins level in the ipsilateral cerebral cortex of rats after transient focal ischaemia. Neuroscience 2001; 107:405-13.
53. Alessandri B, Tsuchida E, Bullock RM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res 1999;845:232-5.
54. Harkany T, Mulder J, Horvath KM, et al. Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (Bay x 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience 2001;108:629-42.
55. Oosterink BJ, Harkany T, Luiten PGM. Post-lesion administration of 5-HT1A receptor agonist 8-OH-DPAT protects cholinergic nucleus basalis neurons against NMDA excitotoxicity. Neuroreport 2003;14:57-60.
56. Kline AE, Yu J, Horvath E, et al. The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats. Neuroscience 2001;106:547-55.
57. Ohman J, Braakman R, Legout V, and Traumatic Brain Injury Study Group. Repinotan (Bay x 3702): a 5HT1A agonist in traumatically brain injured patients. J Neurotrauma 2001;18:1313-21.
58. Lutsep HL. Repinotan Bayer. Curr Opin Investig Drugs 2002;3:924-7.
59. The Enlimolab Acute Stroke Trial Investigators. The Enlimolab Acute Stroke Trial: Final results (abstract). Neurology 1997;48:A270.
60. Cross AJ, Jones JA, Baldwin HA, et al. Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol 1991;104:406-11.
61. Wahlgren NG, the Clomethiazole Acute Stroke Study Collaborative Group. The Clomethiazole Acute Stroke Study Collaborative Group (CLASS): Efficacy results in a subgroup of 545 patients with Total Anterior Circulation Syndrome. Stroke 1998;29:287.
62. Argentino C, Sacchetti ML, Toni D, et al. GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study-Hemodilution + Drug. Stroke 1989;20:1143-9.
63. The SASS Investigators. Ganglioside GM1 in acute ischemic stroke. Stroke 1994;25:1141-8.
64. Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial. Stroke 1994; 25:1552-8.
65. Castillo J, Martinez F, Leira R, et al. Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters. Cerebrovasc Dis 1994;4:56-71.
66. Kammersgaard LP, Rasmussen BH, Jorgensen HS, et al. Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: A case-control study: the Copenhagen Stroke Study. Stroke 2000;31:2251-6.
67. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30:1969-73.
68. Toung TJ, Traystman RJ, Hurn PD. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 1998;29:1666-70.
69. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001;32:980-86.
70. Fayad P, Caplik J, Culligan N, et al. Safety, tolerability, and pharmacokinetics of intravenous BMS-204352, a novel maxi-K channel opener, in patients up to 48 hours after acute ischemic stroke. Cerebrovasc Dis 2000;10(suppl2):71.
71. Olinger CP, Adams HP Jr, Brott TG, et al. High-dose intravenous naloxone for the treatment of acute ischemic stroke. Stroke 1990;21:721-5.
72. Clark WM, Raps EC, Tong DC, et al. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000;31:1234-9.
73. Saxena R, Wijnhoud AD, Carton H, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999;30:993-6.
74. Siren AL, Ehrenreich H. Erythropoetin – a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-84.
75. Müller WE, Koch S, Scheuer K, et al. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53:135-40.
76. de Deyn PP, Reuck JD, Deberdt W, et al. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 1997;28:2347-52.
77. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002;70:133-9.
78. Zusman RM, Chesebro JH, Comerota A, et al. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection. Clin Cardiol 1999;22:559-73.
79. Blatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000;140:67-73.
80. Fisher M, Jonas S, Sacco RL. Prophylactic neuroprotection to improve stroke outcome. Cerebrovasc Dis 1994;4(Suppl): 20-3.
81. Gladstone DJ, Black SE, Hakim AM, Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36.
82. Small DL, Buchan AM. Animal models. Br Med Bull 2000;56:307-17.
83. Fisher M, Brott TG. Emerging therapies for acute ischemic stroke. New therapies on trial. Stroke 2003;34:359-61.